Europace Advance Access originally published online on December 18, 2007
Europace 2008 10(7):821-824; doi:10.1093/europace/eum272
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ARVC and Brugada syndrome
Significance of cardiac autonomic neuropathy in risk stratification of Brugada syndrome
Cardiology Department, Shiraz University of Medical Sciences, Shiraz, Iran
Manuscript submitted 18 June 2007. Accepted after revision 21 November 2007.
* Corresponding author: Cardiology Department, Namazee Hospital, PO Box 71935-1334, Shiraz, Iran. Tel: +98 711 2277181; fax: +98 711 2277182. E-mail address: draslani{at}yahoo.com
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionConclusionReferences |
|---|
Aims: Risk stratification in Brugada syndrome (BS) is controversial especially in asymptomatic individuals. The aim of this study was to evaluate the significance of cardiac autonomic neuropathy (CAN) in BS.
Methods and results: Patients diagnosed with Brugada ECG pattern were enrolled in the study. Four standard cardiac autonomic function tests were performed. The presence of 
2 abnormal test results were considered definite evidence for the presence of CAN. Types 1, 2, and 3 Brugada ECG pattern were found in 28, 56, and 31 patients, respectively. CAN was detected in 13 (46%) patients with type 1 Brugada ECG pattern. In contrast, none of the type 2 or 3 Brugada patients had CAN. Of 13 patients with CAN, 11 had previous history of cardiac events (84%), whereas only 2 of 15 patients without CAN had history of previous cardiac events (13%; P = 0.01). The most noteworthy finding was that all of the type 1 Brugada patients with CAN were male (CAN was not detected in females).
Conclusions: It was concluded that CAN is an important risk indicator in BS. CAN is more common in men. Male gender, per se, is not an independent risk factor for development of ventricular arrhythmia but also CAN, which is an important risk factor in BS, is more common in men; therefore men are susceptible to the development of cardiac events.
Key Words: Arrhythmia, Brugada syndrome, Cardiac autonomic neuropathy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionReferences |
|---|
Brugada syndrome (BS) is characterized by a coved-type ST-segment elevation in leads V1 to V3 and a high incidence of ventricular tachycardia/fibrillation, syncope, and sudden cardiac death in structurally normal hearts.1
–11 The clinical characteristics and the variability of the typical ECG features under autonomic modulation indicate the potential role of the cardiac autonomic nervous system in the pathogenesis and arrhythmogenesis of BS.12 Cardiac autonomic neuropathy (CAN) can be assessed using simple non-invasive tests: the Valsalva manoeuvre, beat-to-beat heart rate variation, postural fall in blood pressure, and the sustained handgrip test. To date, there is no published report regarding clinical evaluation of CAN in BS. Clinical evaluation of CAN in BS is the aim of the present study. |
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionReferences |
|---|
Study population
Between September 2004 and October 2006, patients referred to the Arrhythmia Clinic in southern Iran1
and diagnosed with Brugada ECG pattern were enrolled in the study and were given informed written consent. A 12-lead ECG (at a paper speed of 25 mm/s and 1 mV/10 mm standard gain) was recorded from each subject. All ECG recordings were evaluated by two cardiologists. Brugada type ECG pattern was defined as type 1, 2, or 3. Type 1 pattern has coved ST-segment elevation of 2 mm or greater, followed by an inverted T wave, with little or no isoelectric separation. Type 2 pattern also has a high-takeoff ST-segment elevation of 2 mm or greater with gradually descending ST-segment elevation (remaining 1 mm above the baseline), followed by a positive or biphasic T wave resulting in a saddleback configuration. Type 3 pattern has either coved or saddleback appearance with right precordial ST-segment elevation of <1 mm.13 Type 1 pattern is diagnostic of the Brugada sign, whereas patterns of types 2 and 3 require conversion to the type 1 pattern after challenge with a sodium channel blocking agent to be diagnostic.13 If the standard 12-lead ECG showed type 2 or 3 Brugada pattern, 10 mg/kg of procainamide was intravenously administered in 10 min, with the patient being continuously monitored in the intensive care unit. Type 2 and 3 patterns require conversion to the type 1 pattern after challenge with a sodium channel blocking agent to be diagnostic.
Clinical evaluation of cardiac autonomic neuropathy
Four standard cardiac autonomic function tests14 were performed in the morning after the patients had fasted overnight. To avoid possible confounding factors, patients refrained from physical exercise and partaking of alcohol, caffeine, cigarettes and cigars, and drugs for at least 24 h before the tests. (1) Deep breathing test (as a test of parasympathetic function)15 was performed at six ventilations/min (abnormal RR interval ratio <1.11); (2) Valsalva manoeuvre (as a test of parasympathetic function)15 was done by having the patient blow at 40 mmHg for 15 s (abnormal RR interval ratio <1.21); (3) postural systolic blood pressure change (as a test of sympathetic function)15 was measured with the patient in the recumbent position and again after the patient had been in the standing position for 30 s (abnormal blood pressure decrease >30 mmHg); and (4) Handgrip test (as a test of sympathetic function)15 was measured as the increase in diastolic blood pressure during 30% maximal handgrip (abnormal blood pressure increase <10 mmHg). The presence of 2 abnormal test results was considered evident for the presence of CAN.
Statistical analysis
Statistical analysis was performed using SPSS software (Chicago, IL, USA), and P-values <0.05 were considered significant. Categorical variables were compared using Chi-squared test. Group differences were analyzed by one-way ANOVA followed by Scheffé's multiple comparison tests. Numeric variables were compared using dependent-samples t-test.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionReferences |
|---|
Baseline characteristics
Type 1 Brugada ECG pattern was found in 28 patients (24 spontaneous and 4 after procainamide challenge test). Thirteen patients were symptomatic (seven had syncope, three had ventricular tachycardia/fibrillation based on implantable cardioverter defibrillator (ICD) analysis, and three had aborted sudden death). Type 2 and 3 ECG patterns were found in 56 and 31 patients, respectively.
Cardiac autonomic neuropathy
Cardiac autonomic neuropathy was detected in 13 (46%) patients with type 1 Brugada ECG pattern. In contrast, none of the type 2 or 3 Brugada patients have CAN. Characteristics of type 1, 2, and 3 Brugada patients are listed in Table 1. None of the type 1, 2, or 3 patients were taking drugs or anti-arrhythmics that may have affected the autonomic testing.
|
Characteristics of type 1 Brugada patients with cardiac autonomic neuropathy
From 13 patients with CAN, 11 had history of previous cardiac events (84%) (seven had syncope, three had aborted sudden cardiac death, and one had ventricular fibrillation on ICD analysis), whereas only 2 of 15 patients without CAN had history of previous cardiac events (13%) (Fisher's exact test: P = 0.01) (Table 2). The most noteworthy finding was that all of the type 1 Brugada patients with CAN were male (CAN was not detected in females) (Table 3). Details of autonomic testing of the types 1, 2, and 3 Brugada patients are listed in Table 4. Association between each of the four autonomic testing and previous cardiac events in type 1 Brugada patients is illustrated in Table 5. It is obvious that abnormal postural blood pressure and abnormal handgrip tests (which are indicators of sympathetic dysfunction) are significant predictors of previous cardiac events in type 1 Brugada patients.
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionReferences |
|---|
Brugada syndrome and cardiac autonomic neuropathy
The pathophysiology of BS is still under investigation. Interestingly, unlike other diseases, ventricular fibrillation and sudden death mainly occurs in the resting state, predominantly during sleep.16
,17 The typical ECG changes are variable over time and can be modulated by exercise or pharmacological interventions that interact with the cardiac autonomic innervations. The clinical characteristics and the variability of the typical ECG features under autonomic modulation indicate the potential role of the cardiac autonomic nervous system in the pathogenesis and arrhythmogenesis of BS.
Potential mechanisms of autonomic dysfunction in Brugada syndrome
Increased sympathetic activity has been demonstrated in patients with idiopathic right ventricular outflow tract tachycardia and arrhythmogenic right ventricular cardiomyopathy. In these conditions, however, ventricular tachyarrhythmia is frequently capable of being provoked by exercise or catecholamine and of being suppressed by anti-adrenergic therapy. In contrast, in the BS, ventricular arrhythmias and sudden death occurs mainly at rest or during sleep, suggesting parasympathetic dominance to be a triggering factor. Moreover, ST-segment elevation is augmented by β-blockade or parasympathetic stimulation, whereas it diminishes or disappears with β-adrenergic stimulation. For these reasons, increased sympathetic activity appears to be very unlikely as a mechanism of CAN in BS. Decreased sympathetic activity, as assessed by 123I-MIBG-SPECT imaging, has been shown in patients with BS.12 In patients with BS, however, a reduced adrenergic activity with subsequent dominance of the parasympathetic tone may be discussed as a mechanism of autonomic imbalance. A lack of sympathetic drive and acetylcholine stimulation reduce cyclic adenosine monophosphate production, with a potential impact on protein phosphorylation and spatial heterogeneity of calcium transients, which may be arrhythmogenic.12 This imbalance may be even more intense at times of physiological downregulation of adrenergic activity, which partly explains the propensity for ventricular tachyarrhythmia and sudden death at rest or during sleep in BS.12 Kies et al.18 assessed the cardiac autonomic nervous system in Brugada patients non-invasively. They quantified myocardial pre-synaptic and post-synaptic sympathetic function by means of positron emission tomography with the norepinephrine analogue 11C-hydroxyephedrine (11C-HED) and the non-selective β-blocker 11C-CGP 12177 (11C-CGP). They showed that autonomic innervation in BS describes an enhanced pre-synaptic norepinephrine recycling with preserved β-adrenoceptor density, further supporting the hypothesis of an autonomic dysfunction in BS.
Significance of cardiac autonomic neuropathy in risk stratification of Brugada syndrome
In the present study, we found that CAN is present only in type 1 Brugada ECG pattern and none of type 2 or 3 Brugada patients express evidence of CAN. This finding can explain why type 2 or 3 Brugada patients never experience ventricular arrhythmias and these ECG patterns are considered as normal variations. On the other hand, presence of CAN in 46% of type 1 Brugada patients can explain the higher propensity of ventricular arrhythmias in these patients. In the present study, in a retrospective manner, we also showed a significant association between CAN and occurrence of previous cardiac events in patients with type 1 Brugada ECG pattern. Therefore, CAN may be a risk indicator in patients with BS. We also showed that abnormal postural blood pressure and abnormal handgrip tests (which are indicators of sympathetic dysfunction) are significant predictors of previous cardiac events in type 1 Brugada patients.
Brugada syndrome, male sex, and cardiac autonomic neuropathy
It is well known that male gender is an important risk factor for ventricular arrhythmias and sudden death in BS and men had a five-fold higher risk of sudden death than did women. The exact mechanism(s) of such association is not well described. The basis for this intriguing sex-related distinction was the subject of a recent experimental study19 showing that the presence of a more prominent transient outward current (Ito) in males underlies their predisposition to development of the Brugada phenotype. The less prominent Ito in females was due in large part to more rapid inactivation kinetics of the channel in females.
Although most families thus far described display a male predominance in the manifestation of BS, a recent study by Hong et al.20 highlights a family with a female predominance. The mutation identified, R367H, was the same one previously described as a SUDS mutation in a family displaying a strong male predominance of the Brugada phenotype. This observation suggests that factors other than a specific mutation determine the gender distinction.
The most noteworthy finding of the present study was that all of the type 1 Brugada patients with CAN were male (CAN was not detected in females). In the present study, 13 from 28 (46%) of the type 1 Brugada patients had CAN. Of 13 patients with CAN, all were male (100%). Therefore, the higher incidence of ventricular arrhythmias in men may be due to the higher incidence of CAN in men. This finding is supported by the fact that men in whom CAN was absent never experience previous cardiac events in this study. Therefore, we postulate that male gender, per se, is not an independent risk factor for development of ventricular arrhythmia but also CAN, an important risk factor in BS, is more common in men; therefore men are susceptible to the development of cardiac events.
|
Conclusion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionReferences |
|---|
It is concluded that CAN is an important risk indicator in BS. CAN is more common in men. Male gender, per se, is not an independent risk factor for development of ventricular arrhythmia but also CAN, which is an important risk factor in BS, is more common in men; therefore men are susceptible to development of cardiac events.
Conflict of interest: none declared.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionReferences |
|---|
[1] Babaee Bigi MA, Aslani A, Shahrzad S. Prevalence of Brugada sign in patients presenting with palpitation in southern Iran. Europace (2007) 9:252–5.
[2] Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol (1992) 20:1391–6.[Abstract]
[3] Brugada J, Brugada R, Brugada P. Right bundle branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation (1998) 97:457–60.
[4] Brugada J, Brugada R, Antzelevitch C, Towbin JA, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 105:73–8.
[5] Antzelevitch C, Brugada P, Brugada J, Brugada R, Towbin JA, Nademanee K. Brugada syndrome: 1992–2002 a historical review. J Am Coll Cardiol (2003) 41:1665–71.
[6] Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 392:293–6.[CrossRef][Medline]
[7] Priori SG, Napolitano C, Gasparini M, Pappone C, Bella PD, Brignole M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation (2000) 102:2509–15.
[8] Yan GX, Antzelevitch C. Celluar basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation (1999) 100:1660–6.
[9] Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol (2001) 12:268–72.[CrossRef][Web of Science][Medline]
[10] Miyazaki T, Mitamura H, Hiyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol (1996) 27:1061–70.[Abstract]
[11] Chalvidan T, Deharo JC, Dieuzaide P. Near fatal electrical storm in a patient equipped with an implantable cardioverter-defibrillator for Brugada syndrome. Pace (2000) 23:410–2.[Medline]
[12] Wichter T, Matheja P, Eckardt L, Kies P, Schafers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation (2002) 105:702–6.
[13] Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Circulation (2005) 111:659–70.
[14] Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognosis implications. Ann Intern Med (1980) 92:308–11.[Web of Science][Medline]
[15] Gautschy B, Weidmann P, Gnadinger MP. Autonomic function tests as related to age and gender in normal man. J Mol Med (1986) 64:499–505.
[16] Matsuo K, Kurita T, Inagaki M, Kakishita M, Aihara N, Shimizu W, et al. The circadian pattern of the development ventricular fibrillation in patients with Brugada syndrome. Eur Heart J (1999) 20:465–70.
[17] Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation (1997) 96:2595–600.
[18] Kies P, Wichter T, Schäfers M, Paul M, Schäfers KP, Eckardt L, et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation (2004) 110:3017–22.
[19] Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 106:2004–11.
[20] Hong K, Vatta M, Poungvarin N, Oliva A, Towbin J, Antzelevitch C, Brugada R. SUDS and Brugada syndrome linked by the same SCN5A mutation. Circ J (2003) 196(Suppl 1).
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Europace:
- What role for autonomic dysfunction in Brugada Syndrome? Pathophysiological and prognostic implications
- Thomas Wichter
Europace 2008 10: 782-783.[Full Text]
This article has been cited by other articles:
|
|
 |
|
  T. Wichter What role for autonomic dysfunction in Brugada Syndrome? Pathophysiological and prognostic implications Europace, July 1, 2008; 10(7): 782 - 783. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||